In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

A multicenter brazilian cohort to optimize heart failure treatment using an organized multidisciplinary approach - Optimize Brazil

Session Poster Session 1

Speaker Ricardo Mourilhe Rocha

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : R Mourilhe Rocha (Rio de Janeiro,BR), PPM Spineti (Rio de Janeiro,BR), P Schwartzmann (Ribeirao Petro,BR), F Camazzola (Caxias do Sul,BR), S Rassi (Goiania,BR), AF Freitas Junior (Goiania,BR), JD Souza Neto (Fortaleza,BR), LC Danzmann (Porto Alegre,BR), DC Albuquerque (Rio de Janeiro,BR)

R Mourilhe Rocha1 , PPM Spineti1 , P Schwartzmann2 , F Camazzola3 , S Rassi4 , AF Freitas Junior4 , JD Souza Neto5 , LC Danzmann6 , DC Albuquerque1 , 1State University of Rio de Janeiro (UERJ) - Rio de Janeiro - Brazil , 2Unimed Hospital - Ribeirao Petro - Brazil , 3Hospital Geral de Caxias do Sul - Caxias do Sul - Brazil , 4Federal University of Goias - Goiania - Brazil , 5Hospital de Messejana Dr Carlos Alberto Studart Gomes - Fortaleza - Brazil , 6Lutheran University of Brazil - Porto Alegre - Brazil ,


Introduction: Heart Failure (HF) is a major health problem worldwide, with elevated proportion of deaths and hospitalizations. In Brazil, a national prospective registry demonstrated an even higher rate of death and re-hospitalizations. The treatment is challenging and requires a multidisciplinary initiative to improve pharmacological and non-pharmacological treatment in this population. This comprehensive multidisciplinary approach is the main goal of the Optimize Program and is focused beyond the pharmacological treatment in educating patients and their families about the disease and providing information for self-monitoring.
Purpose: We aimed at assessing the clinical effect of Optimize-HF Program in a prospective multicenter Brazilian cohort of heart failure patients.
Methods: We prospectively included a total of 288 patients (pts) (180 males, 61.07±12.5 y.o.) with heart failure and reduced left ventricular ejection fraction (LVEF) mainly with non-ischemic etiology (178 pts – 61.8%). Pts were followed in HF clinics of six Brazilian centers and received the orientations of the Optimize program.
Results: The baseline characteristics were: LVEF = 33.7±12.2%, EDLV = 65.7±10.5mm, ESLV = 55.2±10.6mm, systolic arterial pressure = 114.9±22 mmHg, heart rate = 77.9±20.4 bpm, 37.8% of the patients  were in NYHA functional class II and 58.7% of the patients were  in NYHA functional class III and IV, 31.8% had atrial fibrillation/flutter, 54.9% had hypertension, 31.9% diabetes mellitus, 35.4% smoking, 18.4% obesity, 7.98% had implantable cardioverter defibrillator or cardiac resynchronization therapy. Patients were treated following the recommendations of the guidelines: 93.4% were using betablockers, 78.1% ACE inhibitors or ARBs, 70.8% ARMs, 2.1% ARNI, 18.4% digoxin, 91.7% diuretics, 28.5% warfarin, 23.6% amiodarone, 11.1% nitrate/hydralazine, and 12.9% ivabradine. The follow-up time was 158,7±131,2 days, with 9.7% of mortality and 20.5% of rehospitalization.  The low mean LVEF and the worse functional class (NYHA III-IV) suggest that this is a high risk HF population. The outcome rate of death and a combined outcome of death or rehospitalization were markedly lower in comparison to the Brazilian National Registry of HF, which showed more than 42% of mortality and rehospitalization over 6 months.
Conclusion: The optimization of HF treatment using a multidisciplinary program showed a lower rate of death and death or rehospitalization. These results suggest the potential benefit of this strategy to improve prognosis of patients with heart failure and reduced LVEF.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are